Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Taiwan Advance Bio-Pharmaceutical Inc. (4186:TWSE), powered by AI.
Taiwan Advance Bio-Pharmaceutical Inc. is currently trading at $10.20. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Taiwan Advance Bio-Pharmaceutical Inc. on Alpha Lenz.
View Taiwan Advance Bio-Pharmaceutical Inc.'s valuation metrics on Alpha Lenz.
“Taiwan Advance Bio-Pharmaceutical Inc.'s ROE is 10.4%. Explore profitability and growth together.”
Ask for details →Taiwan Advance Bio-Pharmaceutical Inc. is a biotechnology company specializing in the development and production of diagnostic solutions and biopharmaceutical products. The firm provides a diverse range of food safety diagnostic testing kits—including ELISA, rapid, and chemical tests—for applications across sectors such as meat, eggs, aquatic products, dairy, and microorganism analysis. Taiwan Advance Bio-Pharmaceutical also offers customization of test kits, laboratory establishment consulting, and manufactures monoclonal and polyclonal antibodies for research and clinical purposes. Beyond food safety, it supplies abused drugs rapid tests and operates centers for testing and identification of drug abuse, providing both urine and hair-based analyses. The company further delivers cell banking services for the storage of newborn and adult stem cells, underscoring its role in regenerative medicine. Founded in 1989 and based in New Taipei City, Taiwan, Taiwan Advance Bio-Pharmaceutical Inc. has built an international footprint, serving markets in Asia, Europe, and North America. Its integrated approach supports the healthcare and pharmaceutical sectors by enhancing safety, diagnostics, and biotechnological innovation.
“Taiwan Advance Bio-Pharmaceutical Inc.'s ROE is 10.4%. Explore profitability and growth together.”
Ask for details →Taiwan Advance Bio-Pharmaceutical Inc. (ticker: 4186) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 165 employees.
The current price is 10.2 with a P/E ratio of -x and P/B of -x.
ROE is 10.36% and operating margin is 10.25%. Annual revenue is $365M.